Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619620 | 0.80 | ALDH1A1 (0.43) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL29535205 | 0.80 | ALDH1A1 (0.43) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL26619622 | 0.80 | ALDH1A1 (0.43) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL6476247 | 0.79 | HTT (0.49) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL2993631 | 0.78 | HTT (0.46) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL5285710 | 0.78 | HTT (0.48) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL30644032 | 0.78 | HTT (0.48) | HTTALDH1A1RAB9AMEN1KMT2A | |
| Hydrogen Peroxide SCHEMBL9456544 | 0.77 | IDO1 (0.46) | HTTALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL14453237 | 0.77 | HTT (0.40) | HTTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8802816 | 0.74 | TSHR (0.50) | HTTALDH1A1MEN1KMT2AXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | HTT 344/4885ALDH1A1 2240/4885RAB9A 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.